| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 07/23/2003 | CN1115341C Substituted N-methyl-N-(4-(1H-benzimidazol-2-yl-amino) piperidin-1-yl)-2-(aryl) butyl) benzamides useful for treatment of allergic diseases |
| 07/22/2003 | US6596772 Relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are |
| 07/22/2003 | US6596761 Cosmetic and dermatological preparation with flavonoids |
| 07/22/2003 | US6596746 Cyclic protein tyrosine kinase inhibitors |
| 07/22/2003 | US6596738 Inhibiting activity to adenosine deaminase (hereinafter described as ADA) An adenosine deaminase inhibiting agent comprising a compound of the formula (I): |
| 07/22/2003 | US6596730 Phenyl urea and phenyl thiourea derivatives |
| 07/22/2003 | US6596721 (6S)- or 10 (6R,S)- tetrahydrofolic acid is crystallized in a polar medium with pH of 3.5 or greater and have a purity 98% |
| 07/22/2003 | US6596718 7-Morpholin-4yl-benzothiazole amide derivatives |
| 07/22/2003 | US6596711 GABA B receptor agonists for use in the treatment of CNS disorders, such as muscle relaxation in spinal spasticity, cardiovascular disorders, asthma, gut motility disorders such as irritable bowel syndrome and gastroesophogeal reflux |
| 07/22/2003 | US6596687 Cell adhesion inhibitors |
| 07/22/2003 | US6596529 Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof |
| 07/22/2003 | US6596525 Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
| 07/22/2003 | US6596319 Such as various cancers, by administering low molecular weight compounds of following properties: extractable from bile of an animal, stimulates monocytes and macrophages, modulates tumor necrosis factor production, not endotoxin |
| 07/22/2003 | US6596296 Three dimensional matrices for growing cells; controlled delivery of therapeutic agents |
| 07/22/2003 | US6596295 Aqueous solution for treating degenerative or autoimmune diseases and/or as an immunomodulatory agent |
| 07/22/2003 | US6596275 Increasing release of PGE-2, IL-10 and/or IL-4; decreasing expression and secretion of IL-1, IL-12 and/or IFM gamma cytokines; decreasing prescence of CD80, CD86 and/or CD40 antigens; having polylysine-cDNA encoding cell nucleus |
| 07/22/2003 | US6596270 Administering the adenoviral gene transfer vector (exogenous) encoding a gene product to a muscle and the vector is neutralized outside of the muscle by systemic neutralizing antibodies; using a chimeric coat protein for cell entry |
| 07/22/2003 | CA2269923C Pharmaceutical compositions containing plasma protein |
| 07/21/2003 | CA2416791A1 A receptor-ligand pairing for immune response |
| 07/21/2003 | CA2368656A1 Receptor-ligand pairing for anti-inflammatory response |
| 07/17/2003 | WO2003057856A2 Dominant negative proteins and methods thereof |
| 07/17/2003 | WO2003057854A2 Novel proteins and nucleic acids encoding same |
| 07/17/2003 | WO2003057829A2 Methods of generating multispecific, multivalent agents from vh and vl domains |
| 07/17/2003 | WO2003057822A2 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| 07/17/2003 | WO2003057730A1 Ligand for g-protein coupled receptor gpr43 and uses thereof |
| 07/17/2003 | WO2003057729A2 Mammal prolactin variants |
| 07/17/2003 | WO2003057725A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| 07/17/2003 | WO2003057722A2 Cyclic tetrapeptide compound and use thereof |
| 07/17/2003 | WO2003057707A1 2-o-( -d-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it |
| 07/17/2003 | WO2003057699A1 Dibenzodiazepine derivates, their preparation and use |
| 07/17/2003 | WO2003057696A1 Deazapurines and uses thereof |
| 07/17/2003 | WO2003057693A1 5-membered cyclic compounds |
| 07/17/2003 | WO2003057676A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 07/17/2003 | WO2003057666A2 Inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | WO2003057252A1 Human mast cell-expressed membrane proteins |
| 07/17/2003 | WO2003057249A1 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
| 07/17/2003 | WO2003057224A1 Apoptosis inductor |
| 07/17/2003 | WO2003057211A1 Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases. |
| 07/17/2003 | WO2003057198A1 Pharmaceutical formulations with modified release |
| 07/17/2003 | WO2003057196A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | WO2003057166A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/17/2003 | WO2003057159A2 Psoriasin expression by breast epithelial cells |
| 07/17/2003 | WO2003057144A2 Change inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | WO2003057141A2 Methods for improving the aesthetic appearance of skin |
| 07/17/2003 | WO2003057133A2 Herbal composition for treating various disorders including psoriasis, a process for preparation thereof and method for treatment of such disorders |
| 07/17/2003 | WO2003056913A1 Nonhuman model animal lacking the ability to control lymphocyte migration |
| 07/17/2003 | WO2003056896A2 Use of cytokines secreted by dendritic cells |
| 07/17/2003 | WO2003038057A3 Genetic vaccine against human immunodeficiency virus |
| 07/17/2003 | WO2003031595A3 Molecules for disease detection and treatment |
| 07/17/2003 | WO2003030827A3 Compositions for and methods of treating and preventing sirs/sepsis |
| 07/17/2003 | WO2003011329A3 Vaccine for prophylaxis and therapy of dermatophytosis in veterinary and human medicine |
| 07/17/2003 | WO2003008410A3 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 07/17/2003 | WO2003000896A3 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE |
| 07/17/2003 | WO2002090566A3 Recombinant tumor specific antibody and use thereof |
| 07/17/2003 | WO2002066057A3 Methods and compositions for preventing and treating neutrophil-mediated diseases |
| 07/17/2003 | WO2002059286A3 Adenylate cyclases |
| 07/17/2003 | WO2002055693A3 Method for inhibiting the expression of a target gene |
| 07/17/2003 | WO2002046190A3 Sulfonamido ether substituted imidazoquinolines |
| 07/17/2003 | WO2002026998A3 Hydrolases |
| 07/17/2003 | WO2002022805A3 Modulation of il-2- and il-15-mediated t cell responses |
| 07/17/2003 | US20030135053 For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics |
| 07/17/2003 | US20030135028 Human serine protease and serpin polypeptides |
| 07/17/2003 | US20030134888 Substituted diaminopyrazoles; treating diseases, such as cancer, inflammatory disorders, restenosis, and cardiovascular disease. coatings for implantable medical devices, such as prostheses, artificial valves, etc. |
| 07/17/2003 | US20030134886 Pharmaceutically active compounds |
| 07/17/2003 | US20030134880 Novel cd23 inhibitors |
| 07/17/2003 | US20030134873 8-phenyl-(1,2,4)triazolo(1,5-a)pyridin-2-yl)-benzamide derivatives |
| 07/17/2003 | US20030134859 Substituted 2-chloro-5-nitrobenzamides; treating retrograde osteoporosis and diabetes mellitus |
| 07/17/2003 | US20030134858 Treatment of inflammation associated disorders, such as arthritis, colon cancer, and Alzheimer's disease |
| 07/17/2003 | US20030134855 P-acylaminomethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2 -yl)-benzamides; treatment of diseases related to the adenosine receptor, such as Alzheimer's disease, depression, drug addiction, Parkinson's and ADHD |
| 07/17/2003 | US20030134854 Treatment of diseases related to the adenosine receptor, such as Alzheimer's disease, depression, drug addiction, neuroprotection, Parkinson's disease, and attention deficit hyperactivity disorder. |
| 07/17/2003 | US20030134850 Hydrazinyl and nitrogen oxide pyrazoles |
| 07/17/2003 | US20030134849 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors |
| 07/17/2003 | US20030134847 New polycyclic azaindole compounds |
| 07/17/2003 | US20030134840 Novel compounds |
| 07/17/2003 | US20030134839 5-(Alkylidene-cycloalkyl)-and 5-(alkylidene-heterocyclyl)-pyrazoles |
| 07/17/2003 | US20030134836 Substituted arylamine derivatives and methods of use |
| 07/17/2003 | US20030134829 X is a ring having at least 4 atoms in the ring; K is hydrocarbyl group; Rh1 is an optional halo group; Rh2 is an optional halo group; at least one of Rh1 and Rh2 is present; Rs is any one of a sulphamate group, a phosphonate, |
| 07/17/2003 | US20030134810 Delivery of pharmacologically active agents associated with polymeric biocompatible materials. Compositions comprising a first, negatively charged pharmacologically active agent such as an oligonucleotide and a polycationic polymer such as |
| 07/17/2003 | US20030134800 Physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. composition weight, (2) hydroxynaphthoic acid |
| 07/17/2003 | US20030134796 Antithrombin for the prevention and therapy of vasculoproliferative disorders |
| 07/17/2003 | US20030134787 Engineered to noncovalently bind to heat shock proteins; (ii) to compositions comprising such conjugate peptides, optionally bound to heat shock protein; and (iii) to methods of using such compositions to induce an immune response in a subject in |
| 07/17/2003 | US20030134430 Novel amino acid sequences for human caenorhabditis elegans-like protein polypeptides |
| 07/17/2003 | US20030134419 Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
| 07/17/2003 | US20030134390 An isolated polynucleotide molecule encoding an IL-21 antagonist polypeptide of specefic amino acid sequence; culturing |
| 07/17/2003 | US20030134334 Use of vascular endothelial growth factor (VEGF) |
| 07/17/2003 | US20030133988 Immunomodulation accomplished by administration of immunomodulatory polynucleotide/microcarrier complexes comprising 3-6 mer immunomodulatory oligonucleotides |
| 07/17/2003 | US20030133984 Comprising poorly water soluble drug, solubilizing component, and surfactant which is semisolid or solid; drug may e.g. be a cyclosporin or a macrolide; immunosuppressants |
| 07/17/2003 | US20030133950 Inducing a desired T helper lymphocyte regulated immune response by delivering an immunogen to a preselected region of the gastrointestinal tract of a patient |
| 07/17/2003 | US20030133934 Method for enhancing the presentation of exogenous antigen by human antigen-presenting cells and opsonized micro particle complexes for applying this method |
| 07/17/2003 | US20030133930 Administering to a patient having an autoimmune disorder an antibody to a B-cell antigens and a carrier; CD22, CD20, CD19, and CD74 or HLA-DR antigen. |
| 07/17/2003 | US20030133913 Producing chemokine receptors, inducing antigen by dendritic cells in vitro, for therapeutic or prophylactic purposes |
| 07/17/2003 | US20030133911 Pneumovirus ns proteins antagonising the interferon (ifn) response |
| 07/17/2003 | US20030133880 Powdery pharmaceutical compositions for inhalation |
| 07/17/2003 | US20030133875 Assay for screening candidate drug for the treatment of inflammatory diseases and methods for treating the same |
| 07/17/2003 | CA2472647A1 Mammal prolactin variants |
| 07/17/2003 | CA2472585A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | CA2472165A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 07/17/2003 | CA2472151A1 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
| 07/17/2003 | CA2472111A1 Human mast cell-expressed membrane proteins |
| 07/17/2003 | CA2472049A1 Dominant negative proteins and methods thereof |